<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19513105</article-id><article-id pub-id-type="pmc">2686100</article-id><article-id pub-id-type="publisher-id">08-PNTD-RA-0323R3</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0000456</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Immunology/Immune Response</subject><subject>Immunology/Immunomodulation</subject><subject>Virology/Immunodeficiency Viruses</subject></subj-group></article-categories><title-group><article-title>Regulatory T Cell Expansion in HTLV-1 and Strongyloidiasis Co-infection Is Associated with Reduced IL-5 Responses to <italic>Strongyloides stercoralis</italic> Antigen</article-title><alt-title alt-title-type="running-head">Regulatory T Cells in HTLV-1/Strongyloidiasis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Montes</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sanchez</surname><given-names>Cesar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Verdonck</surname><given-names>Kristien</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lake</surname><given-names>Jordan E.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez</surname><given-names>Elsa</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Terashima</surname><given-names>Angelica</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nolan</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Dorothy E.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gotuzzo</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>A. Clinton</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Virology Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Medicine, Division of Infectious Diseases, University of California at Los Angeles, Los Angeles, California, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Steinmann</surname><given-names>Peter</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Swiss Tropical Institute, Switzerland</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>montes@bcm.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MM ACW. Performed the experiments: MM CS GL AT. Analyzed the data: MM CS KV JEL EG DEL ACW. Contributed reagents/materials/analysis tools: AT TN DEL ACW. Wrote the paper: MM CS KV JEL EG GL TN DEL EG ACW.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2009</year></pub-date><volume>3</volume><issue>6</issue><elocation-id>e456</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>Montes et al.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Human strongyloidiasis varies from a chronic but limited infection in normal hosts to hyperinfection in patients treated with corticosteroids or with HTLV-1 co-infection. Regulatory T cells dampen immune responses to infections. How human strongyloidiasis is controlled and how HTLV-1 infection affects this control are not clear. We hypothesize that HTLV-1 leads to dissemination of <italic>Strongyloides stercoralis</italic> infection by augmenting regulatory T cell numbers, which in turn down regulate the immune response to the parasite.</p></sec><sec><title>Objective</title><p>To measure peripheral blood T regulatory cells and <italic>Strongyloides stercoralis</italic> larval antigen-specific cytokine responses in strongyloidiasis patients with or without HTLV-1 co-infection.</p></sec><sec><title>Methods</title><p>Peripheral blood mononuclear cells (PBMCs) were isolated from newly diagnosed strongyloidiasis patients with or without HTLV-1 co-infection. Regulatory T cells were characterized by flow cytometry using intracellular staining for CD4, CD25 and FoxP3. PBMCs were also cultured with and without <italic>Strongyloides</italic> larval antigens. Supernatants were analyzed for IL-5 production.</p></sec><sec><title>Results</title><p>Patients with HTLV-1 and <italic>Strongyloides</italic> co-infection had higher parasite burdens. Eosinophil counts were decreased in the HTLV-1 and <italic>Strongyloides</italic> co-infected subjects compared to strongyloidiasis-only patients (70.0 vs. 502.5 cells/mm<sup>3</sup>, p&#x0200a;=&#x0200a;0.09, Mann-Whitney test). The proportion of regulatory T cells was increased in HTLV-1 positive subjects co-infected with strongyloidiasis compared to patients with only strongyloidiasis or asymptomatic HTLV-1 carriers (median&#x0200a;=&#x0200a;17.9&#x00025; vs. 4.3&#x00025; vs. 5.9 p&#x0003c;0.05, One-way ANOVA). <italic>Strongyloides</italic> antigen-specific IL-5 responses were reduced in strongyloidiasis/HTLV-1 co-infected patients (5.0 vs. 187.5 pg/ml, p&#x0200a;=&#x0200a;0.03, Mann-Whitney test). Reduced IL-5 responses and eosinophil counts were inversely correlated to the number of CD4&#x0002b;CD25&#x0002b;FoxP3&#x0002b; cells.</p></sec><sec><title>Conclusions</title><p>Regulatory T cell counts are increased in patients with HTLV-1 and <italic>Strongyloides stercoralis</italic> co-infection and correlate with both low circulating eosinophil counts and reduced antigen-driven IL-5 production. These findings suggest a role for regulatory T cells in susceptibility to <italic>Strongyloides</italic> hyperinfection.</p></sec></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Human strongyloidiasis varies from a mild, controlled infection to a severe frequently fatal disseminated infection depending on the hosts. Patients infected with the retrovirus HTLV-1 have more frequent and more severe forms of strongyloidiasis. It is not clear how human strongyloidiasis is controlled by the immune system and how HTLV-1 infection affects this control. We hypothesize that HTLV-1 leads to dissemination of <italic>Strongyloides stercoralis</italic> by augmenting regulatory T cell numbers, which in turn down regulate the immune response to the parasite. In our study, patients with HTLV-1 and <italic>Strongyloides</italic> co-infection had higher parasite burdens than patients with only strongyloidiasis. Eosinophils play an essential role in control of strongyloidiasis in animal models, and eosinophil counts were decreased in the HTLV-1 and <italic>Strongyloides stercoralis</italic> co-infected subjects compared to patients with only strongyloidiasis. The proportion of T cells with a regulatory cell phenotype was increased in HTLV-1 positive subjects co-infected with strongyloidiasis compared to patients with only strongyloidiasis. IL-5 is a key host molecule in stimulating eosinophil production and activation, and <italic>Strongyloides stercoralis</italic> antigen-specific IL-5 responses were reduced in strongyloidiasis/HTLV-1 co-infected patients. Reduced IL-5 responses and eosinophil counts were inversely correlated to the number of regulatory T cells. These findings suggest a role for regulatory T cells in susceptibility to <italic>Strongyloides</italic> hyperinfection.</p></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>
<italic>Strongyloides stercoralis</italic> infects 60 million individuals in tropical and subtropical areas of the world <xref rid="pntd.0000456-Gill1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pntd.0000456-Mercado1" ref-type="bibr">[3]</xref>. It is unique among helminths in that it can complete its life cycle inside a single human host <xref rid="pntd.0000456-Viney1" ref-type="bibr">[4]</xref>. The clinical presentation of human strongyloidiasis varies with the status of the host's immunity <xref rid="pntd.0000456-Vadlamudi1" ref-type="bibr">[5]</xref>. Immunocompetent individuals develop a chronic, asymptomatic or mildly symptomatic infection. Patients treated with corticosteroids, cancer patients and persons infected with the Human T-cell-lymphotropic virus 1 (HTLV-1), may develop an accelerated form of infection termed hyperinfection, characterized by gastrointestinal and pulmonary hemorrhage, and secondary bacterial infections due to large numbers of parasite larvae migrating from the gut through the lung <xref rid="pntd.0000456-Safdar1" ref-type="bibr">[6]</xref>&#x02013;<xref rid="pntd.0000456-Gotuzzo1" ref-type="bibr">[9]</xref>. <italic>Strongyloides</italic> hyperinfection has a high fatality rate <xref rid="pntd.0000456-Carvalho1" ref-type="bibr">[10]</xref>.</p><p>Animal models have only provided limited understanding of how the host controls <italic>S. stercoralis</italic>, because the parasite cannot complete the lifecycle in mice <xref rid="pntd.0000456-Dawkins1" ref-type="bibr">[11]</xref>. Though murine models are not ideal for this particular parasite, careful studies have suggested a role for innate and adaptative immune mechanisms of control <xref rid="pntd.0000456-Abraham1" ref-type="bibr">[12]</xref>. The innate response requires eosinophils, which kill the larvae <xref rid="pntd.0000456-Rotman1" ref-type="bibr">[13]</xref>. The cytokine IL-5 is essential for development and activation of eosinophils <xref rid="pntd.0000456-Herbert1" ref-type="bibr">[14]</xref>. The adaptive response involves specific antibody production (including IgG and IgE), and granulocytes <xref rid="pntd.0000456-Kerepesi1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pntd.0000456-Ligas1" ref-type="bibr">[17]</xref>. Neutrophils are more important than eosinophils in killing <xref rid="pntd.0000456-Kerepesi1" ref-type="bibr">[15]</xref>. However, eosinophils are required to generate an optimal antibody response <xref rid="pntd.0000456-Herbert1" ref-type="bibr">[14]</xref>, serving as antigen presenting cells <xref rid="pntd.0000456-Padigel1" ref-type="bibr">[18]</xref>. Chemokines attracting eosinophils (eotaxin) and granulocytes (IL-8) are also needed to kill the larvae, presumably by attracting these granulocytes to kill the parasites <xref rid="pntd.0000456-Mir1" ref-type="bibr">[19]</xref>.</p><p>There are few studies on the human immune response to <italic>S. stercoralis</italic> infection <xref rid="pntd.0000456-Keiser1" ref-type="bibr">[7]</xref>. Since hyperinfection develops in transplant and corticosteroid-treated patients, some thought that the cellular immune response might play an important response in controlling infection. HIV is a retrovirus that causes depletion of the cellular immune response and acquired immunodeficiency syndrome (AIDS). However, even with severe depletion of CD4 T cells, AIDS patients control dissemination of <italic>S. stercoralis</italic>
<xref rid="pntd.0000456-Viney2" ref-type="bibr">[20]</xref>. Thus, factors other than the cellular immune response are likely more important in control of strongyloidiasis.</p><p>HTLV-1 is another human retrovirus endemic in Japan, Africa, the Caribbean and South America <xref rid="pntd.0000456-Verdonck1" ref-type="bibr">[8]</xref>. In contrast to patients with AIDS, patients co-infected with <italic>S. stercoralis</italic> and HTLV-1 frequently develop <italic>S. stercoralis</italic> hyperinfection <xref rid="pntd.0000456-Gotuzzo1" ref-type="bibr">[9]</xref>,<xref rid="pntd.0000456-Carvalho1" ref-type="bibr">[10]</xref>,<xref rid="pntd.0000456-Phelps1" ref-type="bibr">[21]</xref>. HTLV-1 and HIV share basic retroviral structures and modes of transmission. Both HTLV-1 and HIV target CD4&#x0002b; T lymphocytes, but, in contrast to HIV infection where T cells are killed, HTLV-1 activates CD4&#x0002b; T cells and induces CD4&#x0002b; T cell proliferation through up-regulation of interleukin-2 (IL-2) and its receptor <xref rid="pntd.0000456-Verdonck1" ref-type="bibr">[8]</xref>, <xref rid="pntd.0000456-Inoue1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pntd.0000456-Ding1" ref-type="bibr">[24]</xref>. The cytokine profile of T cells isolated from patients with HTLV-1 includes T helper 1 (Th1) cytokines (e.g. IFN-&#x003b3;) as well as regulatory cytokines (e.g. IL-10 and TGF&#x003b2;) <xref rid="pntd.0000456-Neva1" ref-type="bibr">[25]</xref>&#x02013;<xref rid="pntd.0000456-Porto1" ref-type="bibr">[27]</xref>. Unlike HIV patients, patients with HTLV-1 are not susceptible to intracellular opportunistic infections <xref rid="pntd.0000456-Verdonck1" ref-type="bibr">[8]</xref>. However, disseminated strongyloidiasis is more common in HTLV-1-infected patients than in HIV patients <xref rid="pntd.0000456-Gotuzzo1" ref-type="bibr">[9]</xref>,<xref rid="pntd.0000456-Phelps1" ref-type="bibr">[21]</xref>.</p><p>Regulatory T cells are increasingly recognized as playing a key role in reducing injurious host inflammatory and immune responses <xref rid="pntd.0000456-Belkaid1" ref-type="bibr">[28]</xref>. Regulatory T cells control the immune response by different mechanisms: cell-to-cell contact, inhibitory cytokines (e.g. TGF-&#x003b2;, IL-10) and by cytokine deprivation <xref rid="pntd.0000456-Pandiyan1" ref-type="bibr">[29]</xref>. These cells prevent an excessive immune response and bystander tissue damage during the host response to infections <xref rid="pntd.0000456-Belkaid1" ref-type="bibr">[28]</xref>. In murine models of <italic>Leishmania major</italic> infection, regulatory T cells prevent complete elimination of the parasite, yet parasite persistence is required for maintaining the protective immune response <xref rid="pntd.0000456-Belkaid2" ref-type="bibr">[30]</xref>. Some studies demonstrate that nematode infections (human and mice) induce regulatory cell expansion <xref rid="pntd.0000456-Anthony1" ref-type="bibr">[31]</xref>. Foxp3 expression levels have been evaluated in patients with HTLV-1 associated myelopathy and asymptomatic carriers with varied results <xref rid="pntd.0000456-Abe1" ref-type="bibr">[32]</xref>,<xref rid="pntd.0000456-Michaelsson1" ref-type="bibr">[33]</xref>. Foxp3 levels inversely correlate with the rate at which cytotoxic T cells kill HTLV-1 infected lymphocytes in an ex-vivo model <xref rid="pntd.0000456-Toulza1" ref-type="bibr">[34]</xref>. Regulatory T cells have not been studied in HTLV-1 and <italic>S stercoralis</italic> infected patients. We hypothesize that HTLV-I leads to dissemination of <italic>Strongyloides stercoralis</italic> by augmenting regulatory T cells (Treg), which in turn down regulate the immune response against this parasite, allowing for the hyperinfection syndrome.</p></sec><sec id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study population and collection of clinical data</title><p>The Instituto de Medicina Tropical &#x02018;Alexander von Humboldt&#x02019; at the Universidad Peruana Cayetano Heredia (IMT AvH - UPCH) in Lima, Peru is a national referral center for the study of HTLV-1 and its associated diseases. Patients with strongyloidiasis are routinely tested for HTLV-1 infection. Between November 2005 and August 2007, all newly diagnosed subjects with strongyloidiasis were invited to participate. Strongyloidiasis diagnosis was confirmed by stool examination. All those with <italic>S. stercoralis</italic> in stool were tested for HTLV-1 infection by Enzyme-Linked Immuno Sorbent Assay (Ortho HTLVI/HTLVII Ab-capture ELISA, Ortho-Clinical Diagnostics, USA) with confirmatory western blot analysis (INNO-LIA HTLVI/II Score, Innogenetics, Belgium). Consenting patients underwent further clinical and laboratory evaluation, including complete blood count (CBC) with differential, flow cytometry analysis and immunological studies of peripheral blood mononuclear cells (PBMCs). Demographic and symptoms data were obtained from patient interviews and reviews of clinical records. Stool and blood samples were collected at the outpatient clinic at the time of enrollment. In addition, asymptomatic HTLV-1 infected patients and healthy HTLV-1 negative subjects were enrolled as controls.</p></sec><sec id="s2b"><title>Ethics</title><p>All participants signed a written informed consent form prior to enrollment in the study. The Institutional Review Board (Comit&#x000e9; Institucional de &#x000c9;tica) of the Universidad Peruana Cayetano Heredia in Lima, Per&#x000fa; approved the study protocol and consent forms.</p></sec><sec id="s2c"><title>Stool examination</title><p>Routine stool evaluation for ova and parasites included direct examination, and spontaneous and fast sedimentation techniques. Stools were examined for <italic>S. stercoralis</italic> using the Baermann technique modified by Lumbreras <xref rid="pntd.0000456-Marcos1" ref-type="bibr">[35]</xref>. <italic>S. stercoralis</italic> parasite load was reported in a semi-quantitative scale as negative, <italic>1&#x0002b;</italic>, <italic>2&#x0002b;</italic>, <italic>3&#x0002b;</italic> or <italic>4&#x0002b;</italic> according to the number of larvae observed under microscopy by personnel who were blinded to the HTLV-1 status of the participant.</p></sec><sec id="s2d"><title>Flow cytometry</title><p>PBMCs were isolated from heparinized blood by density gradient centrifugation (BD Vacutainer CPT Cell Preparation Tube with Sodium Heparin, NJ). Regulatory cells were defined by staining for CD4, CD25, and FoxP3. PBMCs were first stained using Cy-5 conjugated anti-CD4 and phycoerythrine (PE)-conjugated anti-CD25 monoclonal antibodies (BD Biosciences, San Jose, California, USA). After fixing and permeabilizing, the cells were then stained for intracellular FoxP3 using a fluorescein-isothiocyanate (FITC)-conjugated anti-FoxP3 monoclonal antibody (eBiosciences, San Diego, California, USA). Cells were analyzed using a FACScalibur flow cytometer (Beckton Dickinson, Franklin Lakes, New Jersey, USA). Regulatory T cells were identified as CD25&#x0002b; and FoxP3&#x0002b; cells among CD4&#x0002b; cells within the lymphocyte gate. Absolute CD4&#x0002b; cell counts were performed using a 4 color single platform staining of whole blood cells (anti CD3-FITC, CD4-PE, CD45 PerCP and CD8 APC). Flow cytometry analysis used FlowJo software (V.8.5 Tree Star, Ashland, Oregon, USA).</p></sec><sec id="s2e"><title>Antigen-specific cytokine responses to <italic>Strongyloides stercoralis</italic> antigen</title><p>
<italic>S. stercoralis</italic> third-stage larvae (L3) were obtained and cleaned as previously described <xref rid="pntd.0000456-Rotman2" ref-type="bibr">[36]</xref>. Briefly, feces from an infected dog was mixed with bone charcoal and cultured at 25&#x000b0;C for 7 days. The L3 were obtained from the fecal-charcoal culture by the use of a Baermann apparatus and allowed to settle in a tube for 30 minutes. The supernatant was then removed and the pellet of L3 was resuspended with an equal volume of 2&#x00025; liquid low-gelling temperature agar (Sigma Chemical Co., St. Louis, MO, USA) at 37&#x000b0;C. The worm-agar mix was allowed to solidify in the center of a Petri dish and then covered with invertebrate saline. The worms were allowed to migrate out of the solidified agar (leaving most of the bacteria and fecal debris behind) at 37&#x000b0;C for 1 hour. The saline with the clean worms was then centrifuged to pellet the worms. The L3 pellet was frozen at &#x02212;20&#x000b0;C until needed. Crude antigen was obtained by sonication of L3 larvae and centrifugation, supernatant was collected and protein concentration was determined by colorimetric Bradford assay. PBMCs were cultured in RPMI-1640, 10&#x00025; Fetal Bovine Serum antibiotic supplemented media (37&#x000b0;C in 5&#x00025; CO<sub>2</sub>) for 72 hours in the presence or absence of 2-ug/ml crude infective stage <italic>S. stercoralis</italic> larvae (L3) antigen. PBMCs were adjusted to a final concentration of 1&#x000d7;10<sup>6</sup> cells/ml. Supernatants were collected and stored at &#x02212;80&#x000b0;C until cytokine analysis.Interleukin 5 (IL-5) was measured by enzyme-linked immuno sorbent assay on the cell culture supernatant following manufacturer's instructions (BD OptEIA, BD Biosciences, San Diego, California, USA).</p></sec><sec id="s2f"><title>Measurement of HTLV-1 proviral load</title><p>HTLV-1 proviral load in PBMCs was quantified in the strongyloidiasis and HTLV-1 co-infected patients. HTLV-1 proviral load was quantified using a real-time SYBR Green PCR method, as described previously <xref rid="pntd.0000456-Adaui1" ref-type="bibr">[37]</xref>.</p></sec><sec id="s2g"><title>Data analysis</title><p>We compared symptoms and parasite load between patients with and without HTLV-1 by Chi square test. Blood results including regulatory T cell numbers and proportions were compared by ANOVA. The IL-5 responses to antigen stimulation were compared by Mann-Whitney U test. The correlation between the IL-5 responses and regulatory T cells were compared by Spearman's rank test.</p></sec></sec><sec id="s3"><title>Results</title><p>A total of 69 subjects were enrolled in the study. Forty-three patients were identified as infected with <italic>S. stercoralis</italic>. Among them, 3 were HIV positive and excluded from further analysis. Of the 40 remaining <italic>S. stercoralis</italic> patients, 27 were infected with <italic>S. stercoralis</italic> alone, and 13 were co-infected with <italic>S. stercoralis</italic> and HTLV-1. Controls included 17 healthy subjects and 9 patients with HTLV-1 with stools negative for <italic>S. stercoralis</italic>.</p><sec id="s3a"><title>Demographics</title><p>Demographic data are presented in <xref ref-type="table" rid="pntd-0000456-t001">Table 1</xref>. The median age for all patients was 42.0 years (range 22 to 77). Patients with co-infection were slightly older than those with <italic>S. stercoralis</italic> alone (45.0 vs. 39.0 years. p&#x0200a;=&#x0200a;0.36). Gender distribution was similar for both groups, with 55&#x00025; male and 45&#x00025; female. Patients were originally from Andean, Coastal, and Jungle regions in decreasing order of frequency for both groups. Most patients had visited the jungle within three months of onset of gastrointestinal symptoms.</p><table-wrap id="pntd-0000456-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.t001</object-id><label>Table 1</label><caption><title>Demographics and frequency of clinical signs and symptoms of strongyloidiasis patients with and without HTLV-1 co-infection.</title></caption><alternatives><graphic id="pntd-0000456-t001-1" xlink:href="pntd.0000456.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">HTLV-1 carriers</td><td align="left" rowspan="1" colspan="1">Strongyloides&#x0002b;HTLV-1&#x02212;</td><td align="left" rowspan="1" colspan="1">Strongyloides&#x0002b;/HTLV-1&#x0002b;</td><td align="left" rowspan="1" colspan="1">p</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;9)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;27)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (M/F)</td><td align="left" rowspan="1" colspan="1">7/2</td><td align="left" rowspan="1" colspan="1">15/12</td><td align="left" rowspan="1" colspan="1">7/6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">40.0</td><td align="left" rowspan="1" colspan="1">39.0</td><td align="left" rowspan="1" colspan="1">45.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">16/26 (62)</td><td align="left" rowspan="1" colspan="1">7/13 (54)</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">10/26 (38)</td><td align="left" rowspan="1" colspan="1">5/13 (38)</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea/Vomiting (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">7/26 (27)</td><td align="left" rowspan="1" colspan="1">8/9 (89)</td><td align="left" rowspan="1" colspan="1">0.001<sup>&#x0002a;</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal Pain (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">9/26 (35)</td><td align="left" rowspan="1" colspan="1">6/9 (67)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Abd. Distension (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">10/26 (38)</td><td align="left" rowspan="1" colspan="1">3/9 (33)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Flatulence (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">11/26 (42)</td><td align="left" rowspan="1" colspan="1">6/9 (67)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight loss (&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">10/26 (38)</td><td align="left" rowspan="1" colspan="1">5/11 (45)</td><td align="left" rowspan="1" colspan="1">0.69</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>Clinical data was obtained from newly diagnosed patients with strongyloidiasis by stool modified Baermann sedimentation method and tested for HTLV-1 co-infection. Age and gender were similar among strongyloidiasis patients with or without HTLV-1 co-infection. Gastrointestinal signs and symptoms were more frequently reported among HTLV-1 co-infected patients. Table shows proportion of patients reporting symptoms. Frequencies were compared between <italic>S. stercoralis</italic> groups by Chi square test, &#x0002a;&#x0200a;=&#x0200a;p&#x0003c;0.05 (Lima, Peru).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Symptoms</title><p>Abdominal pain, diarrhea, flatulence, nausea, vomiting, and increasing abdominal girth were the most common complaints in <italic>S. stercoralis</italic> groups, with over 50&#x00025; of patients affected. Patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection reported more symptoms than those only infected with <italic>S. stercoralis</italic> (<xref ref-type="table" rid="pntd-0000456-t001">Table 1</xref>).</p></sec><sec id="s3c"><title>Stool analysis</title><p>
<italic>S. stercoralis</italic> and HTLV-1 co-infected patients showed more parasites in stool samples compared with patients infected with <italic>S. stercoralis</italic> only. A high parasite burden (3&#x0002b; or 4&#x0002b; larvae) was noted in 10 (83&#x00025;) of twelve of the co-infected patients. Conversely, patients with just <italic>S. stercoralis</italic> had a low burden of disease (84&#x00025; were 1&#x0002b; or 2&#x0002b;) (p&#x0003c;0.001, Chi-square test, <xref ref-type="fig" rid="pntd-0000456-g001">Figure 1</xref>). Other parasites were found in the stool of 51&#x00025; of all patients, including <italic>Blastocystis hominis</italic> (39&#x00025;), <italic>Trichuris trichiura</italic> (10&#x00025;), hookworms (8&#x00025;), <italic>Giardia lamblia</italic> (5&#x00025;), and <italic>Ascaris lumbricoides</italic> (2.5&#x00025;).</p><fig id="pntd-0000456-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.g001</object-id><label>Figure 1</label><caption><title>Patients with strongyloidiasis and HTLV-1 co-infection (n&#x0200a;=&#x0200a;12) had more <italic>Strongyloides stercoralis</italic> larvae found in stool when compared to strongyloidiasis-only patients (n&#x0200a;=&#x0200a;25).</title><p>A semi-quantitative measure of <italic>Strongyloides stercoralis</italic> parasite load was determined at the time of diagnosis according to the number of larvae observed in stool sediment after Baermann concentration (range from1&#x0002b; to 4&#x0002b;). Parasite load determination was made before the HTLV-1 status was known. HTLV-1 carriers had higher parasite loads (3&#x0002b; and 4&#x0002b;) when compared to the non HTLV-1 group (10 out of 12 vs. 4 out of 25 respectively; p&#x0003c;0.001, Chi square test, Lima, Peru).</p></caption><graphic xlink:href="pntd.0000456.g001"/></fig></sec><sec id="s3d"><title>Blood analysis</title><p>Median hemoglobin and hematocrit were lower in the <italic>S. stercoralis</italic>/HTLV-1 co-infected group compared to HTLV-1 asymptomatic carriers and <italic>S. stercoralis</italic>-only patients (12.8 versus 13.8 versus 14.1 g/dl, p&#x0200a;=&#x0200a;0.11; and 38 versus 41 and 42&#x00025; p&#x0200a;=&#x0200a;0.054 One way ANOVA). Total white blood cell counts and neutrophil counts did not differ significantly among the groups. HTLV-1 asymtpmatic carriers did not show increased eosinophil numbers. Among <italic>S. stercoralis</italic> infected subjects there was a trend towards lower median eosinophils in patients co-infected with HTLV-1 (4&#x00025; versus 7&#x00025;; 200 versus 511 cells/mm<sup>3</sup> (<xref ref-type="table" rid="pntd-0000456-t002">Table 2</xref>).</p><table-wrap id="pntd-0000456-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.t002</object-id><label>Table 2</label><caption><title>Blood analysis, flow cytometry and interleukin-5 responses to <italic>Strongyloides stercoralis</italic> larval antigens A peripheral blood sample was obtained at enrollment from all strongyloidiasis patients.</title></caption><alternatives><graphic id="pntd-0000456-t002-2" xlink:href="pntd.0000456.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">Healthy Controls</td><td align="left" rowspan="1" colspan="1">HTLV-1 carrier</td><td align="left" rowspan="1" colspan="1">Strongyloidiasis&#x0002b;HTLV-1&#x02212;</td><td align="left" rowspan="1" colspan="1">Strongyloidiasis&#x0002b;HTLV-1&#x0002b;</td><td align="left" rowspan="1" colspan="1">p</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;17)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;9)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;27)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">13.8</td><td align="left" rowspan="1" colspan="1">14.1</td><td align="left" rowspan="1" colspan="1">12.80</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematocrit (&#x00025;)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">6200</td><td align="left" rowspan="1" colspan="1">7500</td><td align="left" rowspan="1" colspan="1">7000</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">4745</td><td align="left" rowspan="1" colspan="1">4564</td><td align="left" rowspan="1" colspan="1">3900</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Eosinophil &#x00025;</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0.02&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">Eosinophils (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">511</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">0.01&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">721</td><td align="left" rowspan="1" colspan="1">1166</td><td align="left" rowspan="1" colspan="1">819</td><td align="left" rowspan="1" colspan="1">962</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulatory T-cell (&#x00025;)</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">5.9&#x00025;</td><td align="left" rowspan="1" colspan="1">4.3&#x00025;</td><td align="left" rowspan="1" colspan="1">17.9&#x00025;</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulatory T-cell count</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">233</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001&#x0002a;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><p>Samples were analyzed before HTLV-1 status was known. Numbers represent median of all parameters analyzed. Complete peripheral blood cell count showed lower hemoglobin and hematocrit levels in the HTLV-1 co-infected group. White blood cell, neutrophil, eosinophil, and lymphocyte proportions were not significantly different among groups, although a tendency to lower absolute eosinophil count was observed in the HTLV-1 infected group. Regulatory T cells were significantly increased in patients with strongyloidiasis and HTLV-1 co-infection (&#x0002a;&#x0200a;=&#x0200a;p&#x0003c;0.05, One way ANOVA, Lima, Peru).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>Flow cytometry analysis</title><p>The median CD4&#x0002b; and CD8&#x0002b; T-cell count were similar in strongyloidiasis patients regardless of their HTLV-1 status (<xref ref-type="table" rid="pntd-0000456-t002">Table 2</xref>). By contrast, HTLV-1 co-infected patients had an expanded CD4&#x0002b;CD25<sup>hi</sup> lymphocyte population. Furthermore, the proportion of CD4&#x0002b; T-cells with regulatory T-cell phenotype (CD4&#x0002b;CD25&#x0002b;FoxP3&#x0002b;) was significantly increased in the HTLV-1 co-infected patients (median proportion of CD4&#x0002b; T-cells that were CD25&#x0002b;FoxP3&#x0002b;: 17.9&#x00025;) when compared to all other groups (p&#x0003c;0.0001 One way ANOVA, <xref ref-type="table" rid="pntd-0000456-t002">Table 2</xref>, <xref ref-type="fig" rid="pntd-0000456-g002">Figures 2</xref> and <xref ref-type="fig" rid="pntd-0000456-g003">3</xref>).</p><fig id="pntd-0000456-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.g002</object-id><label>Figure 2</label><caption><title>Flow cytometry analysis showing increased proportions of CD4&#x0002b;CD25hi T cells and CD4&#x0002b;CD25&#x0002b;FoxP3&#x0002b; regulatory T cells in peripheral blood of patients with strongyloidiasis and HTLV-1 co-infection.</title><p>Representative flow cytometry analysis of peripheral blood mononuclear cells comparing a patient with strongyloidiasis without HTLV-1 co-infection (left) to strongylioidiasis/HTLV-1 co-infected patient (right). Upper figures show CD4 and CD25 staining of cells within the lymphocyte gate. Note population of CD4&#x0002b;CD25hi cells in the HTLV-1 co-infected patient suggesting regulatory T cell phenotype. Lower figures show CD4&#x0002b; lymphocytes stained with CD25 and intracellular staining with FoxP3 confirming that CD4&#x0002b;CD25hi cells are indeed FoxP3&#x0002b; (regulatory T cells).</p></caption><graphic xlink:href="pntd.0000456.g002"/></fig><fig id="pntd-0000456-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.g003</object-id><label>Figure 3</label><caption><title>Increased proportions of regulatory T cells in strongyloidiasis/HTLV-1 co-infected patients.</title><p>Comparison of regulatory T cell proportions (CD25&#x0002b;FoxP3&#x0002b; among CD4&#x0002b; T-cells) between healthy controls (blue, n&#x0200a;=&#x0200a;17), patients with strongyloidiasis without HTLV-1 infection (red, n&#x0200a;=&#x0200a;27), HTLV-1 asymptomatic carriers (orange, n&#x0200a;=&#x0200a;9) and strongyloidiasis/HTLV-1 co-infected patients (green, n&#x0200a;=&#x0200a;13). Co-infected patients had a significant increase of regulatory T cells compared to non-HTLV-1 patients. (&#x0002a;&#x0200a;=&#x0200a;P&#x0003c;0.05, One-way ANOVA). Lima, Peru.</p></caption><graphic xlink:href="pntd.0000456.g003"/></fig></sec><sec id="s3f"><title>Interleukin-5 responses to <italic>Strongyloides</italic> antigen</title><p>PBMC's from strongyloidiasis patients produced IL-5 in response to <italic>S. stercoralis</italic> infective stage larvae crude antigen. However, the IL-5 response was reduced in <italic>S. stercoralis</italic> and HTLV-1 co-infected patients (10 vs 299 pg/ml respectively, p&#x0200a;=&#x0200a;0.0004, Mann-Whitney test, <xref ref-type="fig" rid="pntd-0000456-g004">Figure 4</xref>). An inverse correlation was observed between the number of regulatory T-cells and IL-5 cytokine responses (Spearman r&#x0200a;=&#x0200a;&#x02212;0.39, p&#x0200a;=&#x0200a;0.03, <xref ref-type="fig" rid="pntd-0000456-g005">Figure 5</xref>).</p><fig id="pntd-0000456-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.g004</object-id><label>Figure 4</label><caption><title>IL-5 responses to larval <italic>Strongyloides stercoralis</italic> antigens are decreased in patients with strongyloidiasis and HTLV-1 co-infection (n&#x0200a;=&#x0200a;13) compared to HTLV-1 negative subjects with strongyloidiasis (n&#x0200a;=&#x0200a;27).</title><p>Peripheral blood mononuclear cells from newly diagnosed strongyloidiasis patients were cultured with or without <italic>Strongyloides stercoralis</italic> infective-stage larval antigen. Culture supernatants were analyzed for IL-5 production. Patients with HTLV-1 co-infection had significantly decreased IL-5 responses (&#x0002a; p&#x0200a;=&#x0200a;0.0004, Mann Whitney test).</p></caption><graphic xlink:href="pntd.0000456.g004"/></fig><fig id="pntd-0000456-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000456.g005</object-id><label>Figure 5</label><caption><title>Increased numbers of regulatory T cells correlates with reduced IL-5 responses to <italic>Strongyloides stercoralis</italic> larval antigens.</title><p>Patients with higher regulatory T cell numbers showed lower IL-5 responses to <italic>Strongyloides stercoralis</italic> infective-stage crude antigen. An inverse correlation was determined by Sperman non-parametric correlation analysis (Spearman r&#x0200a;=&#x0200a;&#x02212;0.38, p&#x0200a;=&#x0200a;0.03).</p></caption><graphic xlink:href="pntd.0000456.g005"/></fig></sec><sec id="s3g"><title>Characteristics of the HTLV-1 proviral load</title><p>Proviral load data were available for 9 of the 13 HTLV-1 co-infected patients (mean 1566 copies/10<sup>4</sup> PBMCs; ranged from 1442 to 5460). These patients had a significantly higher mean proviral load than did asymptomatic carriers (mean 561 copies/10<sup>4</sup> PBMCs; range 1 to 4773) and were similar to HTLV-1-associated myelopathy patients (mean 1783 copies/10<sup>4</sup> PBMCs; range 142 to 8641), as reported elsewhere <xref rid="pntd.0000456-Adaui1" ref-type="bibr">[37]</xref>.</p></sec></sec><sec id="s4"><title>Discussion</title><p>In this study, we demonstrate that immunocompetent patients with <italic>S. stercoralis</italic> infection have lower worm burdens and higher eosinophil counts compared to patients who are co-infected with HTLV-1 and normal controls. The immunocompetent patients also produce IL-5 in response to stimulation with <italic>S. stercoralis</italic> larval antigens. By contrast, patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection have reduced IL-5 responses to parasite antigens, which may lead to decreased eosinophil count. We also noted increased proportions of CD4&#x0002b;CD25&#x0002b;FoxP3&#x0002b; regulatory T cells in patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection compared to either normal controls or patients infected with either HTLV-1 or <italic>S. stercoralis</italic> only. The proportion of lymphocytes expressing this phenotype was inversely correlated with antigen-driven IL-5 responses. Thus, augmented regulatory T cell function may explain the defective eosinophil numbers in <italic>S.stercoralis</italic> patients co-infected with HTLV-1.</p><p>HTLV-1 is an important risk factor for <italic>Strongyloides</italic> dissemination, but the mechanisms are poorly understood <xref rid="pntd.0000456-Marcos2" ref-type="bibr">[38]</xref>. Previous studies have demonstrated lower eosinophil counts, decreased production of IL-5, and increased production of interferon gamma in patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection <xref rid="pntd.0000456-Carvalho1" ref-type="bibr">[10]</xref>.</p><p>IL-5 is a key growth and activation factor for eosinophils <xref rid="pntd.0000456-Rothenberg1" ref-type="bibr">[39]</xref>. Eosinophils play a key role in clearance of other helminths larvae <xref rid="pntd.0000456-Klion1" ref-type="bibr">[40]</xref>. Several mechanisms may be involved including direct cytotoxicity and antibody dependant cellular cytotoxicity <xref rid="pntd.0000456-Klion1" ref-type="bibr">[40]</xref>.</p><p>We reasoned that regulatory T cells might be responsible for the reduced IL-5 and eosinophil responses in <italic>S. stercoralis</italic> and HTLV-1 co-infected patients. Indeed, the proportion of CD4&#x0002b; cells that were CD25&#x0002b;FoxP3&#x0002b; was dramatically increased in patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection. These levels are higher than have previously been described in humans. Furthermore, those with increased proportions of CD25&#x0002b;FoxP3&#x0002b; cells had decreased antigen-driven production of IL-5 and lower eosinophil counts. Since HTLV-1 can augment expression of CD25, we also re-analyzed the data without including CD25 expression in the definition of regulatory cells (i.e. CD4&#x0002b;FoxP3&#x0002b;). We also performed an analysis using CD127 expression (low or negative) to define regulatory cells. In all of these analyses, the results were similar. Taken together, these data strongly suggest that Tregs may suppress antigen driven function of T cells, which influences the function of eosinophils.</p><p>Pro-viral loads were also elevated in the strongyloidiasis and HTLV-1 co-infected patients, similar to levels increased for other HTLV-1 associated diseases like HTLV-1 associated myelopathy. This suggests that this expanded regulatory T-cell population may be induced by HTLV-1-<italic>S. stercoralis</italic> co-infection or as a response to the proinflammatory effects of these infections. Further studies are needed to determine whether the expansion is in HTLV-1 infection of the Treg cells.</p><p>In summary, we have demonstrated that patients with <italic>S. stercoralis</italic> and HTLV-1 co-infection do not control <italic>S. stercoralis</italic> infection as well as patients with <italic>S. stercoralis</italic> only as indicated by the increase in the number of larvae in stool samples. This defect in immune host response is associated with lower eosinophil counts and decreased antigen-driven production of IL-5. This reduced response is inversely correlated with the proportion of CD4 cells, which are CD4&#x0002b;CD25&#x0002b;FoxP3&#x0002b;, suggesting a role for these cells in blunting antigen-driven protective responses. Additional data is needed to determine whether regulatory T cells are increased because they are HTLV-1 infected or as a response to parasite infection, and to explore mechanisms for suppression of eosinophil counts and function.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p>This work was supported by NIH Research Grant No. RO1 TW007642 funded by the Fogarty International Center to MM, NIH Frant No. D43 TW006569 funded by the Fogarty International Center to ACW, and the Directorate-General for Development Cooperation (DGDC) of the Belgian Government (framework agreement 02, project 95501) and the Flemish Interuniversity Council (VLIR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pntd.0000456-Gill1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gill</surname><given-names>GV</given-names></name><name><surname>Welch</surname><given-names>E</given-names></name><name><surname>Bailey</surname><given-names>JW</given-names></name><name><surname>Bell</surname><given-names>DR</given-names></name><name><surname>Beeching</surname><given-names>NJ</given-names></name></person-group>
<year>2004</year>
<article-title>Chronic Strongyloides stercoralis infection in former British Far East prisoners of war.</article-title>
<source>QJM</source>
<volume>97</volume>
<fpage>789</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="pmid">15569810</pub-id></element-citation></ref><ref id="pntd.0000456-Siddiqui1"><label>2</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name><name><surname>Berk</surname><given-names>S</given-names></name></person-group>
<year>2006</year>
<article-title>Strongyloidiasis.</article-title>
<person-group person-group-type="editor"><name><surname>Guerrant</surname><given-names>RL</given-names></name><name><surname>Walker</surname><given-names>DH</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group>
<source>Tropical Infectious Diseases: Principles, pathogens, and practice</source>
<publisher-loc>Philadelphia</publisher-loc>
<publisher-name>Elsevier, Churchill, Livingstone</publisher-name>
<fpage>1274</fpage>
<lpage>1285</lpage>
</element-citation></ref><ref id="pntd.0000456-Mercado1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercado</surname><given-names>R</given-names></name><name><surname>Jercic</surname><given-names>MI</given-names></name><name><surname>Alcayaga</surname><given-names>S</given-names></name><name><surname>de Paula</surname><given-names>FM</given-names></name><name><surname>Ueta</surname><given-names>MT</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Seroepidemiological aspects of human Strongyloides stercoralis infections in Chile.</article-title>
<source>Rev Inst Med Trop Sao Paulo</source>
<volume>49</volume>
<fpage>247</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">17823755</pub-id></element-citation></ref><ref id="pntd.0000456-Viney1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viney</surname><given-names>ME</given-names></name></person-group>
<year>2006</year>
<article-title>The biology and genomics of Strongyloides.</article-title>
<source>Med Microbiol Immunol</source>
<volume>195</volume>
<fpage>49</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">16538445</pub-id></element-citation></ref><ref id="pntd.0000456-Vadlamudi1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vadlamudi</surname><given-names>RS</given-names></name><name><surname>Chi</surname><given-names>DS</given-names></name><name><surname>Krishnaswamy</surname><given-names>G</given-names></name></person-group>
<year>2006</year>
<article-title>Intestinal strongyloidiasis and hyperinfection syndrome.</article-title>
<source>Clin Mol Allergy</source>
<volume>4</volume>
<fpage>8</fpage>
<pub-id pub-id-type="pmid">16734908</pub-id></element-citation></ref><ref id="pntd.0000456-Safdar1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Safdar</surname><given-names>A</given-names></name><name><surname>Malathum</surname><given-names>K</given-names></name><name><surname>Rodriguez</surname><given-names>SJ</given-names></name><name><surname>Husni</surname><given-names>R</given-names></name><name><surname>Rolston</surname><given-names>KV</given-names></name></person-group>
<year>2004</year>
<article-title>Strongyloidiasis in patients at a comprehensive cancer center in the United States.</article-title>
<source>Cancer</source>
<volume>100</volume>
<fpage>1531</fpage>
<lpage>1536</lpage>
<pub-id pub-id-type="pmid">15042689</pub-id></element-citation></ref><ref id="pntd.0000456-Keiser1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>PB</given-names></name><name><surname>Nutman</surname><given-names>TB</given-names></name></person-group>
<year>2004</year>
<article-title>Strongyloides stercoralis in the Immunocompromised Population.</article-title>
<source>Clin Microbiol Rev</source>
<volume>17</volume>
<fpage>208</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="pmid">14726461</pub-id></element-citation></ref><ref id="pntd.0000456-Verdonck1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verdonck</surname><given-names>K</given-names></name><name><surname>Gonzalez</surname><given-names>E</given-names></name><name><surname>Van Dooren</surname><given-names>S</given-names></name><name><surname>Vandamme</surname><given-names>AM</given-names></name><name><surname>Vanham</surname><given-names>G</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Human T-lymphotropic virus 1: recent knowledge about an ancient infection.</article-title>
<source>Lancet Infect Dis</source>
<volume>7</volume>
<fpage>266</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="pmid">17376384</pub-id></element-citation></ref><ref id="pntd.0000456-Gotuzzo1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gotuzzo</surname><given-names>E</given-names></name><name><surname>Terashima</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>H</given-names></name><name><surname>Tello</surname><given-names>R</given-names></name><name><surname>Infante</surname><given-names>R</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>60</volume>
<fpage>146</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">9988339</pub-id></element-citation></ref><ref id="pntd.0000456-Carvalho1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>EM</given-names></name><name><surname>Da Fonseca Porto</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis.</article-title>
<source>Parasite Immunol</source>
<volume>26</volume>
<fpage>487</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="pmid">15771684</pub-id></element-citation></ref><ref id="pntd.0000456-Dawkins1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawkins</surname><given-names>HJ</given-names></name><name><surname>Grove</surname><given-names>DI</given-names></name></person-group>
<year>1982</year>
<article-title>Attempts to establish infections with Strongyloides stercoralis in mice and other laboratory animals.</article-title>
<source>J Helminthol</source>
<volume>56</volume>
<fpage>23</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">6978359</pub-id></element-citation></ref><ref id="pntd.0000456-Abraham1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abraham</surname><given-names>D</given-names></name><name><surname>Rotman</surname><given-names>HL</given-names></name><name><surname>Haberstroh</surname><given-names>HF</given-names></name><name><surname>Yutanawiboonchai</surname><given-names>W</given-names></name><name><surname>Brigandi</surname><given-names>RA</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Strongyloides stercoralis: protective immunity to third-stage larvae inBALB/cByJ mice.</article-title>
<source>Exp Parasitol</source>
<volume>80</volume>
<fpage>297</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">7895840</pub-id></element-citation></ref><ref id="pntd.0000456-Rotman1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rotman</surname><given-names>HL</given-names></name><name><surname>Yutanawiboonchai</surname><given-names>W</given-names></name><name><surname>Brigandi</surname><given-names>RA</given-names></name><name><surname>Leon</surname><given-names>O</given-names></name><name><surname>Gleich</surname><given-names>GJ</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice.</article-title>
<source>Exp Parasitol</source>
<volume>82</volume>
<fpage>267</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">8631378</pub-id></element-citation></ref><ref id="pntd.0000456-Herbert1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbert</surname><given-names>DR</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>NA</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><name><surname>Schad</surname><given-names>GA</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Role of IL-5 in innate and adaptive immunity to larval Strongyloides stercoralis in mice.</article-title>
<source>J Immunol</source>
<volume>165</volume>
<fpage>4544</fpage>
<lpage>4551</lpage>
<pub-id pub-id-type="pmid">11035095</pub-id></element-citation></ref><ref id="pntd.0000456-Kerepesi1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kerepesi</surname><given-names>LA</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><name><surname>Schad</surname><given-names>GA</given-names></name><name><surname>Lustigman</surname><given-names>S</given-names></name><name><surname>Herbert</surname><given-names>DR</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Human immunoglobulin G mediates protective immunity and identifies protective antigens against larval Strongyloides stercoralis in mice.</article-title>
<source>J Infect Dis</source>
<volume>189</volume>
<fpage>1282</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="pmid">15031798</pub-id></element-citation></ref><ref id="pntd.0000456-Herbert2"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbert</surname><given-names>DR</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><name><surname>Schad</surname><given-names>GA</given-names></name><name><surname>Abraham</surname><given-names>D</given-names></name></person-group>
<year>2002</year>
<article-title>The role of B cells in immunity against larval Strongyloides stercoralis in mice.</article-title>
<source>Parasite Immunol</source>
<volume>24</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">11874564</pub-id></element-citation></ref><ref id="pntd.0000456-Ligas1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ligas</surname><given-names>JA</given-names></name><name><surname>Kerepesi</surname><given-names>LA</given-names></name><name><surname>Galioto</surname><given-names>AM</given-names></name><name><surname>Lustigman</surname><given-names>S</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Specificity and mechanism of immunoglobulin M (IgM)- and IgG-dependent protective immunity to larval Strongyloides stercoralis in mice.</article-title>
<source>Infect Immun</source>
<volume>71</volume>
<fpage>6835</fpage>
<lpage>6843</lpage>
<pub-id pub-id-type="pmid">14638770</pub-id></element-citation></ref><ref id="pntd.0000456-Padigel1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Padigel</surname><given-names>UM</given-names></name><name><surname>Hess</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Lok</surname><given-names>JB</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice.</article-title>
<source>J Infect Dis</source>
<volume>196</volume>
<fpage>1844</fpage>
<lpage>1851</lpage>
<pub-id pub-id-type="pmid">18190266</pub-id></element-citation></ref><ref id="pntd.0000456-Mir1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mir</surname><given-names>A</given-names></name><name><surname>Benahmed</surname><given-names>D</given-names></name><name><surname>Igual</surname><given-names>R</given-names></name><name><surname>Borras</surname><given-names>R</given-names></name><name><surname>O'Connor</surname><given-names>JE</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Eosinophil-selective mediators in human strongyloidiasis.</article-title>
<source>Parasite Immunol</source>
<volume>28</volume>
<fpage>397</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">16879311</pub-id></element-citation></ref><ref id="pntd.0000456-Viney2"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viney</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Omoding</surname><given-names>NE</given-names></name><name><surname>Bailey</surname><given-names>JW</given-names></name><name><surname>Gardner</surname><given-names>MP</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Why does HIV infection not lead to disseminated strongyloidiasis?</article-title>
<source>J Infect Dis</source>
<volume>190</volume>
<fpage>2175</fpage>
<lpage>2180</lpage>
<pub-id pub-id-type="pmid">15551217</pub-id></element-citation></ref><ref id="pntd.0000456-Phelps1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phelps</surname><given-names>KR</given-names></name></person-group>
<year>1993</year>
<article-title>Strongyloides hyperinfection in patients coinfected with HTLV-I and S. stercoralis.</article-title>
<source>Am J Med</source>
<volume>94</volume>
<fpage>447</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="pmid">8475941</pub-id></element-citation></ref><ref id="pntd.0000456-Inoue1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoue</surname><given-names>J</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Tsuru</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name></person-group>
<year>1986</year>
<article-title>Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1.</article-title>
<source>EMBO J</source>
<volume>5</volume>
<fpage>2883</fpage>
<lpage>2888</lpage>
<pub-id pub-id-type="pmid">3024966</pub-id></element-citation></ref><ref id="pntd.0000456-Satoh1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Toma</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Takara</surname><given-names>M</given-names></name><name><surname>Shiroma</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.</article-title>
<source>Clin Exp Immunol</source>
<volume>127</volume>
<fpage>354</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">11876761</pub-id></element-citation></ref><ref id="pntd.0000456-Ding1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Nair</surname><given-names>AM</given-names></name><name><surname>Michael</surname><given-names>B</given-names></name><name><surname>Boris-Lawrie</surname><given-names>K</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation.</article-title>
<source>J Virol</source>
<volume>77</volume>
<fpage>11027</fpage>
<lpage>11039</lpage>
<pub-id pub-id-type="pmid">14512551</pub-id></element-citation></ref><ref id="pntd.0000456-Neva1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neva</surname><given-names>FA</given-names></name><name><surname>Filho</surname><given-names>JO</given-names></name><name><surname>Gam</surname><given-names>AA</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Freitas</surname><given-names>V</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis.</article-title>
<source>J Infect Dis</source>
<volume>178</volume>
<fpage>1856</fpage>
<lpage>1859</lpage>
<pub-id pub-id-type="pmid">9815251</pub-id></element-citation></ref><ref id="pntd.0000456-Carvalho2"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>EM</given-names></name><name><surname>Bacellar</surname><given-names>O</given-names></name><name><surname>Porto</surname><given-names>AF</given-names></name><name><surname>Braga</surname><given-names>S</given-names></name><name><surname>Galvao-Castro</surname><given-names>B</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>27</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">11404513</pub-id></element-citation></ref><ref id="pntd.0000456-Porto1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Porto</surname><given-names>AF</given-names></name><name><surname>Neva</surname><given-names>FA</given-names></name><name><surname>Bittencourt</surname><given-names>H</given-names></name><name><surname>Lisboa</surname><given-names>W</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis.</article-title>
<source>Parasite Immunol</source>
<volume>23</volume>
<fpage>503</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="pmid">11589779</pub-id></element-citation></ref><ref id="pntd.0000456-Belkaid1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belkaid</surname><given-names>Y</given-names></name></person-group>
<year>2007</year>
<article-title>Regulatory T cells and infection: a dangerous necessity.</article-title>
<source>Nat Rev Immunol</source>
<volume>7</volume>
<fpage>875</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="pmid">17948021</pub-id></element-citation></ref><ref id="pntd.0000456-Pandiyan1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pandiyan</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>J</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>
<year>2007</year>
<article-title>CD4&#x0002b;CD25&#x0002b;Foxp3&#x0002b; regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4&#x0002b; T cells.</article-title>
<source>Nat Immunol</source>
<volume>8</volume>
<fpage>1353</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="pmid">17982458</pub-id></element-citation></ref><ref id="pntd.0000456-Belkaid2"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belkaid</surname><given-names>Y</given-names></name><name><surname>Piccirillo</surname><given-names>CA</given-names></name><name><surname>Mendez</surname><given-names>S</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Sacks</surname><given-names>DL</given-names></name></person-group>
<year>2002</year>
<article-title>CD4&#x0002b;CD25&#x0002b; regulatory T cells control Leishmania major persistence and immunity.</article-title>
<source>Nature</source>
<volume>420</volume>
<fpage>502</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="pmid">12466842</pub-id></element-citation></ref><ref id="pntd.0000456-Anthony1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anthony</surname><given-names>RM</given-names></name><name><surname>Rutitzky</surname><given-names>LI</given-names></name><name><surname>Urban</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Stadecker</surname><given-names>MJ</given-names></name><name><surname>Gause</surname><given-names>WC</given-names></name></person-group>
<year>2007</year>
<article-title>Protective immune mechanisms in helminth infection.</article-title>
<source>Nat Rev Immunol</source>
<volume>7</volume>
<fpage>975</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="pmid">18007680</pub-id></element-citation></ref><ref id="pntd.0000456-Abe1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Uchihashi</surname><given-names>K</given-names></name><name><surname>Kazuto</surname><given-names>T</given-names></name><name><surname>Osaka</surname><given-names>A</given-names></name><name><surname>Yanagihara</surname><given-names>K</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Foxp3 expression on normal and leukemic CD4&#x0002b;CD25&#x0002b; T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells.</article-title>
<source>Eur J Haematol</source>
<volume>81</volume>
<fpage>209</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="pmid">18510697</pub-id></element-citation></ref><ref id="pntd.0000456-Michaelsson1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michaelsson</surname><given-names>J</given-names></name><name><surname>Barbosa</surname><given-names>HM</given-names></name><name><surname>Jordan</surname><given-names>KA</given-names></name><name><surname>Chapman</surname><given-names>JM</given-names></name><name><surname>Brunialti</surname><given-names>MK</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>The frequency of CD127low expressing CD4&#x0002b;CD25high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis.</article-title>
<source>BMC Immunol</source>
<volume>9</volume>
<fpage>41</fpage>
<pub-id pub-id-type="pmid">18664281</pub-id></element-citation></ref><ref id="pntd.0000456-Toulza1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toulza</surname><given-names>F</given-names></name><name><surname>Heaps</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>GP</given-names></name><name><surname>Bangham</surname><given-names>CR</given-names></name></person-group>
<year>2008</year>
<article-title>High frequency of CD4&#x0002b;FoxP3&#x0002b; cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response.</article-title>
<source>Blood</source>
<volume>111</volume>
<fpage>5047</fpage>
<lpage>5053</lpage>
<pub-id pub-id-type="pmid">18094326</pub-id></element-citation></ref><ref id="pntd.0000456-Marcos1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcos</surname><given-names>L</given-names></name><name><surname>Terashima</surname><given-names>A</given-names></name><name><surname>Samalvides</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>H</given-names></name><name><surname>Lindo</surname><given-names>F</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>[Thiabendazole for the control of Strongyloides stercoralis infection in a hyperendemic area in Peru].</article-title>
<source>Rev Gastroenterol Peru</source>
<volume>25</volume>
<fpage>341</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="pmid">16333389</pub-id></element-citation></ref><ref id="pntd.0000456-Rotman2"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rotman</surname><given-names>HL</given-names></name><name><surname>Schnyder-Candrian</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>P</given-names></name><name><surname>Nolan</surname><given-names>TJ</given-names></name><name><surname>Schad</surname><given-names>GA</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>IL-12 eliminates the Th-2 dependent protective immune response of mice to larval Strongyloides stercoralis.</article-title>
<source>Parasite Immunol</source>
<volume>19</volume>
<fpage>29</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">9121838</pub-id></element-citation></ref><ref id="pntd.0000456-Adaui1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adaui</surname><given-names>V</given-names></name><name><surname>Verdonck</surname><given-names>K</given-names></name><name><surname>Best</surname><given-names>I</given-names></name><name><surname>Gonzalez</surname><given-names>E</given-names></name><name><surname>Tipismana</surname><given-names>M</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.</article-title>
<source>J Neurovirol</source>
<volume>12</volume>
<fpage>456</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">17162661</pub-id></element-citation></ref><ref id="pntd.0000456-Marcos2"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcos</surname><given-names>LA</given-names></name><name><surname>Terashima</surname><given-names>A</given-names></name><name><surname>Dupont</surname><given-names>HL</given-names></name><name><surname>Gotuzzo</surname><given-names>E</given-names></name></person-group>
<year>2008</year>
<article-title>Strongyloides hyperinfection syndrome: an emerging global infectious disease.</article-title>
<source>Trans R Soc Trop Med Hyg</source>
<volume>102</volume>
<fpage>314</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">18321548</pub-id></element-citation></ref><ref id="pntd.0000456-Rothenberg1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name></person-group>
<year>2006</year>
<article-title>The eosinophil.</article-title>
<source>Annu Rev Immunol</source>
<volume>24</volume>
<fpage>147</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="pmid">16551246</pub-id></element-citation></ref><ref id="pntd.0000456-Klion1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klion</surname><given-names>AD</given-names></name><name><surname>Nutman</surname><given-names>TB</given-names></name></person-group>
<year>2004</year>
<article-title>The role of eosinophils in host defense against helminth parasites.</article-title>
<source>J Allergy Clin Immunol</source>
<volume>113</volume>
<fpage>30</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">14713904</pub-id></element-citation></ref></ref-list></back></article>